^{ATTORNEY ADVERTISING.
PRIOR RESULTS DO NOT GUARANTEE A SIMILAR OUTCOME.}

Bextra is a COX 2 drug manufactured by Pfizer.  When Bextra was first released in 2001, Bextra packages included a warning about side effects such as stomach pain, diarrhea, heartburn, back pain, headache, nausea, and upper respiratory infection. In November 2002, Pfizer, upon the FDA’s orders, strengthened the Contraindications, Warnings, and Adverse Reactions sections Bextra’s prescribing information.

On April 7, 2005, Pfizer withdrew Bextra from the market at the FDA’s request.  The FDA requested the withdrawal because of the incidence among Bextra users of heart attacks, strokes, and a potentially fatal skin condition called Stevens Johnson Syndrome.

On November 9, 2004, a study presented to the American Heart Association indicated that Bextra might carry a higher risk of fatal heart attacks, as much as two times, and cardiac problems than other COX 2 inhibitors. Bextra also appears to increase a patient’s risk of stroke.  In light of this evidence, the FDA has strongly urged physicians to limit the number of prescriptions for Bextra and to consider Bextra alternatives when administering care. 

Bextra has also been linked to Stevens Johnson Syndrome, toxic epidermal necrolysis and exfoliative dermatitis, as well as assorted allergic reactions.  Stevens Johnson Syndrome and Toxic Epidermal Necrolysis (TEN) are two forms of the skin disease that can cause rash, skin peeling, and sores on the mucous membranes.  Both Stevens Johnson Syndrome and Toxic Epidermal Necrolysis can be life threatening.

Stevens Johnson Syndrome is an immune-complex–mediated hypersensitivity disorder.  Sufferers of Stevens Johnson Syndrome demonstrate a blistering of mucous membranes, typically in the mouth, eyes, and vagina, and patchy areas of rash.  Sufferers of toxic epidermal necrolysis also experience a blistering of mucous membranes.  In addition, the entire epidermis peels off in sheets from large areas of the body. Both Stevens Johnson Syndrome and Toxic Epidermal Necrolysis can be life threatening.

The FDA has stated that close to one million people had used Bextra before the warnings were changed.  Many of these Bextra patients are now bringing lawsuits against Pfizer, claiming they were misinformed, lied to, and harmed as a result of inadequate testing procedures

If you or a loved one has taken Bextra and subsequently developed Stevens Johnson Syndrome, Toxic Epidermal Necrolysis, or suffered a heart attack or stroke, contact us to meet with an experienced Bextra attorney to evaluate your claim. 

Milberg LLP
One Pennsylvania Plaza, 49th Fl.
New York, NY, 10119-0165
Phone number: (800) 320-5081
Email: contactus@milberg.com
Website: http://www.milberg.com

^{ATTORNEY ADVERTISING.
PRIOR RESULTS DO NOT GUARANTEE A SIMILAR OUTCOME.}

Bextra Lawyers Disclaimer: The above information about Bextra side effects is not intended to be or to replace legal advice from bextra lawyers. Consult a Milberg Bextra side effects lawyer for individual advice regarding your own possible Bextra class action lawsuit litigation. Confer with your doctor or other qualified medical professional before taking any drug and before changing your own personal healthcare regimen.